BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36608132)

  • 41. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
    Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
    Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
    Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
    Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
    Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
    J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased expression of TRIM21 indicates unfavorable outcome and promotes cell growth in breast cancer.
    Zhou W; Zhang Y; Zhong C; Hu J; Hu H; Zhou D; Cao M
    Cancer Manag Res; 2018; 10():3687-3696. PubMed ID: 30288100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Ubiquitin E3 Ligase TRIM21 Promotes Hepatocarcinogenesis by Suppressing the p62-Keap1-Nrf2 Antioxidant Pathway.
    Wang F; Zhang Y; Shen J; Yang B; Dai W; Yan J; Maimouni S; Daguplo HQ; Coppola S; Gao Y; Wang Y; Du Z; Peng K; Liu H; Zhang Q; Tang F; Wang P; Gao S; Wang Y; Ding WX; Guo G; Wang F; Zong WX
    Cell Mol Gastroenterol Hepatol; 2021; 11(5):1369-1385. PubMed ID: 33482392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A role for EMT in CD73 regulation in breast cancer.
    Hasmim M; Berchem G; Janji B
    Oncoimmunology; 2022; 11(1):2152636. PubMed ID: 36465484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production.
    Young JA; Sermwittayawong D; Kim HJ; Nandu S; An N; Erdjument-Bromage H; Tempst P; Coscoy L; Winoto A
    J Biol Chem; 2011 Feb; 286(8):6521-31. PubMed ID: 21183682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
    Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
    J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intratumoral CD8
    Virassamy B; Caramia F; Savas P; Sant S; Wang J; Christo SN; Byrne A; Clarke K; Brown E; Teo ZL; von Scheidt B; Freestone D; Gandolfo LC; Weber K; Teply-Szymanski J; Li R; Luen SJ; Denkert C; Loibl S; Lucas O; Swanton C; Speed TP; Darcy PK; Neeson PJ; Mackay LK; Loi S
    Cancer Cell; 2023 Mar; 41(3):585-601.e8. PubMed ID: 36827978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
    Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
    Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
    [No Abstract]   [Full Text] [Related]  

  • 53. PTPRO-related CD8
    Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
    Front Immunol; 2022; 13():947841. PubMed ID: 36003382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.
    Flores-Santibáñez F; Fernández D; Meza D; Tejón G; Vargas L; Varela-Nallar L; Arredondo S; Guixé V; Rosemblatt M; Bono MR; Sauma D
    Immunology; 2015 Dec; 146(4):582-94. PubMed ID: 26331349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
    Leclerc BG; Charlebois R; Chouinard G; Allard B; Pommey S; Saad F; Stagg J
    Clin Cancer Res; 2016 Jan; 22(1):158-66. PubMed ID: 26253870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
    Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
    J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining High-Z Sensitized Radiotherapy with CD73 Blockade to Boost Tumor Immunotherapy.
    Chen Q; Chen J; Zhang Q; Yang P; Gu R; Ren H; Dai Y; Huang S; Wu J; Wu X; Hu Y; Yuan A
    ACS Nano; 2023 Jul; 17(13):12087-12100. PubMed ID: 37327456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
    O'Melia MJ; Manspeaker MP; Thomas SN
    Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
    Chang WI; Han MG; Kang MH; Park JM; Kim EE; Bae J; Ahn S; Kim IA
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):845-858. PubMed ID: 33642128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.